- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
bimekizumab is an approved drug (EMA (2021))
Compound class: Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized Phase 2 monoclonal antibody targeting both IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis are reported in . Claimed in patent WO2008047134 as CA028_0496 .
|No information available.|
|Summary of Clinical Use|
|First-in-human clinical trial was NCT02529956 which reported clinically-meaningful efficacy  and lead to further development of bimekizumab in IL-17A- and IL-17 F-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, chronic plaque psoriasis and ankylosing ppondylitis. Click here to link to ClinicalTrials.gov's list of Phase 2 bimekizumab trials.
The EMA approved bimekizumab as a treatment for psoriasis in August 2021.
|Mechanism Of Action and Pharmacodynamic Effects|
|Antibody binds to IL-17A, IL-17F and the IL-17A/F heterodimer, neutralising their biological activity . Dual antagonists of IL-17A and IL-17F may be more effective than a sole antagonist in treating IL-17 mediated diseases.|